论文部分内容阅读
肿瘤是由基因异常引起的:包括癌基因激活和抑癌基因的功能失活,直接纠正这些异常是肿瘤治疗的关键。然而,我们还没有发展出任何有效适合这些基因组的技术。分子生物学研究分析论证了异常基因产物、激活的信号转导途径和肿瘤特异的细胞表面抗原在肿瘤中的作用。分子靶药物被用于在mRNA和蛋白水平抑制肿瘤的发展,一些靶药物甚至在主细胞内对肿瘤进行控制。与传统的化疗药物相比,分子靶药物对肿瘤具有很高的特异性和稳定性。这些药物的作用取决于其相应靶位点的功能,而对药物的疗效预测需要依靠合适的分子生物学技术比如DNA微点阵技术。
Tumor is caused by gene abnormalities: Including the activation of oncogenes and the function inactivation of tumor suppressor genes, direct correction of these abnormalities is the key to cancer treatment. However, we have not developed any technology that is well suited to these genomes. Molecular biology studies have demonstrated the role of aberrant gene products, activated signal transduction pathways and tumor-specific cell surface antigens in oncology. Molecular targeted drugs are used to inhibit the development of tumors at the mRNA and protein level, and some target drugs even control tumors in the host cell. Compared with the traditional chemotherapy drugs, molecular target drugs have high specificity and stability of the tumor. The role of these drugs depends on the function of their corresponding target sites, and the prediction of the efficacy of drugs depends on the appropriate molecular biology techniques such as DNA microarray technology.